Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3590804rdf:typepubmed:Citationlld:pubmed
pubmed-article:3590804lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3590804lifeskim:mentionsumls-concept:C0027697lld:lifeskim
pubmed-article:3590804lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:3590804lifeskim:mentionsumls-concept:C0547040lld:lifeskim
pubmed-article:3590804lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:3590804pubmed:issue7lld:pubmed
pubmed-article:3590804pubmed:dateCreated1987-7-14lld:pubmed
pubmed-article:3590804pubmed:abstractTextIn 5 cases with minimal change nephritis Cyclosporine A has been added to the conventional steroid therapy, when relapse of nephrotic syndrome occurred while reducing the daily prednisolone dose. The intended cyclosporine trough level ranged from 250 ng/ml to 450 ng/ml whole blood, estimated by the RIA method. Proteinuria disappeared in 4 out of the 5 cases, in the other one urinary protein excretion was strikingly reduced. In the 4 cases with complete remission of proteinuria prednisolone was tapered. These patients have cyclosporine A as the sole immunosuppressive drug since 56 weeks and do not show proteinuria. Side effects of cyclosporine therapy have been slight deterioration of kidney function in 2 out of the 5 cases and the occurrence of hypertension in 4 patients.lld:pubmed
pubmed-article:3590804pubmed:languagegerlld:pubmed
pubmed-article:3590804pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3590804pubmed:citationSubsetIMlld:pubmed
pubmed-article:3590804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3590804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3590804pubmed:statusMEDLINElld:pubmed
pubmed-article:3590804pubmed:monthAprlld:pubmed
pubmed-article:3590804pubmed:issn0043-5325lld:pubmed
pubmed-article:3590804pubmed:authorpubmed-author:KopsaHHlld:pubmed
pubmed-article:3590804pubmed:authorpubmed-author:BalckePPlld:pubmed
pubmed-article:3590804pubmed:authorpubmed-author:StockenhuberF...lld:pubmed
pubmed-article:3590804pubmed:authorpubmed-author:Sunder-Plassm...lld:pubmed
pubmed-article:3590804pubmed:authorpubmed-author:DerflerKKlld:pubmed
pubmed-article:3590804pubmed:issnTypePrintlld:pubmed
pubmed-article:3590804pubmed:day3lld:pubmed
pubmed-article:3590804pubmed:volume99lld:pubmed
pubmed-article:3590804pubmed:ownerNLMlld:pubmed
pubmed-article:3590804pubmed:authorsCompleteYlld:pubmed
pubmed-article:3590804pubmed:pagination242-5lld:pubmed
pubmed-article:3590804pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:meshHeadingpubmed-meshheading:3590804-...lld:pubmed
pubmed-article:3590804pubmed:year1987lld:pubmed
pubmed-article:3590804pubmed:articleTitle[Cyclosporin therapy in minimal change nephritis].lld:pubmed
pubmed-article:3590804pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3590804pubmed:publicationTypeEnglish Abstractlld:pubmed